Shanghai Lixin Pharmaceutical Research and Development

Shanghai Lixin Pharmaceutical Research and Development is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets oncology and metabolic diseases, with a strong emphasis on endocrine-related cancers such as breast and prostate cancer. Its lead candidate, LX-039, is a selective estrogen receptor degrader (SERD) currently in clinical development for the treatment of ER-positive breast cancer. Lixin Pharmaceutical leverages its internal R&D capabilities to advance a pipeline of targeted therapies, including PI3K inhibitors and androgen receptor antagonists. The company is headquartered in the Zhangjiang Hi-Tech Park and aims to provide high-quality, affordable innovative medicines for patients globally.